An interventional study of High flow nasal cannula and nebulized normal saline in Airway Obstruction, Respiratory Infection and Mucus; Plug, sponsored by Cardarelli Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.
Sponsored by Cardarelli Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The application of HFNC therapy in patients with airway stent, improving both humidification and clearance of the airway secretion, could potentially reduce the risk of mucoid impaction, respiratory infections and granulation. HFNC therapy could be superior to nebulization of normal saline (usual care) in order to keep the stent cleaned, reducing, by inference, the risk of complications, as defined above.
148 studies on the registry are indexed under Airway Obstruction; 26 are open to participants now.
This study's planned enrollment of 30 is below the median of 52 across 93 interventional studies indexed under Airway Obstruction.
Browse Airway Obstruction studies →Cardarelli Hospital is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with High Flow Nasal Cannula minimum twenty (20) minutes three times a day (one \[1\] hour a day in total) and up to 10 hours a day in total, according to patient's preferences.
Device: High flow nasal cannula
Treatment with nebulization of 4-8 cc of normal saline three times daily
Device: nebulized normal saline
home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
incidence of mucous plugging associated with airway stent in HFNC group
mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 7 days from stent placement
incidence of mucous plugging associated with airway stent in HFNC group
mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 30 days from stent placement
incidence of mucous plugging associated with airway stent in HFNC group
mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 60 days from stent placement
incidence of mucous plugging associated with airway stent in HFNC group
mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 90 days from stent placement
incidence of mucous plugging associated with airway stent in nebulized saline group
mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 7 days from stent placement
incidence of mucous plugging associated with airway stent in nebulized saline group
mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 30 days from stent placement
incidence of mucous plugging associated with airway stent in nebulized saline group
mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 60 days from stent placement
incidence of granuloma associated with airway stent in HFNC group
granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 90 days from stent placement
incidence of granuloma associated with airway stent in nebulized saline group
granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 7 days from stent placement
incidence of granuloma associated with airway stent in nebulized saline group
granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 30 days from stent placement
incidence of granuloma associated with airway stent in nebulized saline group
granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 60 days from stent placement
incidence of granuloma associated with airway stent in nebulized saline group
granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area
Time frame: within 90 days from stent placement
incidence of respiratory infection associated with airway stent in HFNC group
symptoms of respiratory infection + radiologic and/or bronchoscopic signs of infection + need of antibiotic therapy
Time frame: within 90 days from stent placement
incidence of respiratory infection associated with airway stent in nebulized saline group
symptoms of respiratory infection + radiologic and/or bronchoscopic signs of infection + need of antibiotic therapy
Time frame: within 90 days from stent placement
adherence to home treatment with HFNC in patients with airway stent, as assesed by time of daily utilization
minutes a day spent on HFNC
Time frame: within 90 days from stent placement
adherence to home treatment with nebulization of normal saline in patients with airway stent, as assesed by time of daily utilization
times a day spent on nebulization
Time frame: within 90 days from stent placement
incidence of adverse events due to home treatment with HFNC in patients with airway stent
incidence of malfunction of the device; incidence of complications as assessed by clinical examination (cough, headache, rhinitis)
Time frame: within 90 days from stent placement
incidence of adverse events due to home treatment with nebulization of normal saline in patients with airway stent
incidence of malfunction of the device; incidence of complications as assessed by clinical examination (cough, headache, rhinitis)
Time frame: within 90 days from stent placement
Satisfaction of home treatment with HFNC by Cough and sputum assessment questionnaire (CASA-Q)
Cough and sputum assessment questionnaire (CASA-Q) to evaluate both severity of cough and sputum production to quality of life impairment (minimum value 0, maximum value 100; higher scores mean worse outcome)
Time frame: within 90 days from stent placement
Satisfaction of home treatment with nebulized saline by Cough and sputum assessment questionnaire CASA-Q
Cough and sputum assessment questionnaire (CASA-Q) to evaluate both severity of cough and sputum production to quality of life impairment (minimum value 0, maximum value 100; higher scores mean worse outcome)
Time frame: within 90 days from stent placement
incidence of airway stent colonization in HFNC group
positive bronchial aspirate culture
Time frame: within 90 days from stent placement
incidence of airway stent colonization in nebulized saline group
positive bronchial aspirate culture
Time frame: within 90 days from stent placement
all cause-mortality in HFNC group
Time frame: within 90 days from stent placement
all cause-mortality in nebulized saline group
Time frame: within 90 days from stent placement
mortality due to respiratory infection in HFNC group
Time frame: within 90 days from stent placement
mortality due to respiratory infection in nebulized saline group
Time frame: within 90 days from stent placement
Started Jan 2024 (actual). Primary completion is estimated for Nov 2024, 10 months after the start.
Of 36 non-industry interventional studies with no phase under Airway Obstruction, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 37. This study's planned 10 months is below that.
Counting every sponsor, half of 44 studies reached it within 16 months; a quarter within 3 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardarelli Hospital